Skip to main
  1. Stocks
  2. Xenon Pharmaceuticals
  3. Forecast
XENE

Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target

Xenon Pharmaceuticals (XENE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 60%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Xenon Pharmaceuticals is viewed favorably because azetukalner has the strongest efficacy dataset yet in focal seizures, with −53.2% median seizure reduction versus −10.4% on placebo and RR50 of 54.8% versus 20.8% in a heavily refractory population averaging at least 5 prior failed medications. The company’s epilepsy franchise is further de-risked by more than 1,500 patient years of safety and exposure data, a filed NDA, and a practical profile of day-one therapeutic dosing, no titration, and no DRESS risk, which could support broad adoption and meaningful commercial penetration. While the psychiatry program is paused pending safety clarity, its pain assets add longer-dated optionality, and the wholly owned Nav1.7 and Kv7 programs provide additional mechanistic breadth in a large unmet-need market.

Bears say

Xenon Pharmaceuticals is facing a weakened fundamental outlook because its psychiatric program was paused after a DSMB review identified neuropsychiatric adverse events, forcing management to remove the MDD opportunity from valuation and increasing uncertainty around the therapeutic window. The setback is compounded by X-NOVA2 closing at about 360 patients versus a 450 target, with topline now expected in 1Q27, while the company still must prove that dosing changes can preserve efficacy without worsening safety. Although epilepsy remains the core value driver and the NDA has been submitted, the stock carries added near-term risk from regulatory delay, competitive pressure, commercial-execution uncertainty, and financing needs until cash flow turns positive.

Xenon Pharmaceuticals (XENE) has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 60% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xenon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Xenon Pharmaceuticals (XENE) Analyst Forecast & Price Prediction

Get the latest Xenon Pharmaceuticals (XENE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Xenon Pharmaceuticals (XENE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xenon Pharmaceuticals (XENE) Forecast

Analysts have given Xenon Pharmaceuticals (XENE) a Buy based on their latest research and market trends.

According to 10 analysts, Xenon Pharmaceuticals (XENE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xenon Pharmaceuticals (XENE)


Xenon Pharmaceuticals (XENE) Analyst Forecast & Price Prediction

Get the latest Xenon Pharmaceuticals (XENE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Xenon Pharmaceuticals (XENE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover XENE stock data and trends